• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Sci Rep . Predictive factors for the presence and long-term persistence of SARS-CoV-2 antibodies in healthcare and university workers

tetano

Editor, Senior Moderator
Sci Rep


. 2022 Jun 13;12(1):9790.
doi: 10.1038/s41598-022-13450-4.
Predictive factors for the presence and long-term persistence of SARS-CoV-2 antibodies in healthcare and university workers


Céline Grégoire[SUP] #[/SUP][SUP] 1 [/SUP], Pascale Huynen[SUP] #[/SUP][SUP] 2 3 [/SUP], Stéphanie Gofflot[SUP] 4 [/SUP], Laurence Seidel[SUP] 5 [/SUP], Nathalie Maes[SUP] 5 [/SUP], Laura Vranken[SUP] 6 [/SUP], Sandra Delcour[SUP] 6 [/SUP], Michel Moutschen[SUP] 7 8 [/SUP], Marie-Pierre Hayette[SUP] 2 3 [/SUP], Philippe Kolh[SUP] 9 10 [/SUP], Pierrette Melin[SUP] 2 3 [/SUP], Yves Beguin[SUP] 11 4 12 [/SUP]



Affiliations

Abstract

While patient groups at risk for severe COVID-19 infections are now well identified, the risk factors associated with SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) transmission and immunization are still poorly understood. In a cohort of staff members of a Belgian tertiary academic hospital tested for SARS-CoV-2 antibodies during the early phase of the pandemic and followed-up after 6 weeks, 3 months and 10 months, we collected personal, occupational and medical data, as well as symptoms based on which we constructed a COVID-19 score. Seroprevalence was higher among participants in contact with patients or with COVID-19 confirmed subjects or, to a lesser extent, among those handling respiratory specimens, as well as among participants reporting an immunodeficiency or a previous or active hematological malignancy, and correlated with several symptoms. In multivariate analysis, variables associated with seropositivity were: contact with COVID-19 patients, immunodeficiency, previous or active hematological malignancy, anosmia, cough, nasal symptoms, myalgia, and fever. At 10 months, participants in contact with patients and those with higher initial COVID-19 scores were more likely to have sustained antibodies, whereas those with solid tumors or taking chronic medications were at higher risk to become seronegative.
 
Back
Top Bottom